Bio-Me raises NOK10m

Both, existing and new investors participated in the financing round, with new investors contributing the majority of the capital. The company said it will use the assets to further progressits clinical pipeline and explore new business opportunities for shorter-term revenue generation. 

The five-year-old company has developed a novel gut microbiome analysis tool in collaboration with Thermo Fisher Scientific, called Precision Microbiome Profiling (PMP™) that offers a targeted qPCR-based approach to microbiome profiling/diagnosis through the analysis of 100 - 200 samples in two hours.

Morten Isaksen, CEO of Bio-Me said that  the company will  position PMP™ as the preferred solution for therapeutic microbiome companies.